Full Text View
Tabular View
No Study Results Posted
Related Studies
Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients (TILT)
This study is ongoing, but not recruiting participants.
Study NCT00105235   Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: March 10, 2005   Last Updated: May 13, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Liver Disease
Liver Transplantation
Additional conditions recognized in this trial
Liver Diseases
More general conditions related to this trial
Digestive System Diseases
Interventions listed in this trial
Alemtuzumab
Cyclosporine
Mycophenolate mofetil
Tacrolimus
Liver transplant
Immunosuppression withdrawal
Additional drug interventions recognized in this trial
Cyclosporins
Mycophenolic Acid
More general drug interventions related to this trial
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Antirheumatic Agents
Dermatologic Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)
Immune Tolerance Network


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services